KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Emergent BioSolutions (EBS) EBIT Margin: 2010-2025

Historic EBIT Margin for Emergent BioSolutions (EBS) over the last 16 years, with Sep 2025 value amounting to 33.10%.

  • Emergent BioSolutions' EBIT Margin rose 1115.00% to 33.10% in Q3 2025 from the same period last year, while for Sep 2025 it was 15.02%, marking a year-over-year increase of 3055.00%. This contributed to the annual value of -10.42% for FY2024, which is 5881.00% up from last year.
  • As of Q3 2025, Emergent BioSolutions' EBIT Margin stood at 33.10%, which was up 2,815.09% from 1.14% recorded in Q2 2025.
  • Over the past 5 years, Emergent BioSolutions' EBIT Margin peaked at 39.13% during Q4 2021, and registered a low of -407.00% during Q2 2024.
  • Over the past 3 years, Emergent BioSolutions' median EBIT Margin value was -4.88% (recorded in 2024), while the average stood at -54.71%.
  • Per our database at Business Quant, Emergent BioSolutions' EBIT Margin tumbled by 32,032bps in 2024 and then soared by 40,814bps in 2025.
  • Over the past 5 years, Emergent BioSolutions' EBIT Margin (Quarterly) stood at 39.13% in 2021, then plummeted by 5,588bps to -16.75% in 2022, then soared by 91bps to -15.84% in 2023, then surged by 1,096bps to -4.88% in 2024, then skyrocketed by 1,115bps to 33.10% in 2025.
  • Its EBIT Margin was 33.10% in Q3 2025, compared to 1.14% in Q2 2025 and 22.46% in Q1 2025.